Modified T-Cells for Bladder Cancer Treatment Application
Summary
The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.
What changed
The United States Patent and Trademark Office (USPTO) has published a patent application, US20260083849A1, concerning a method for treating bladder cancer. The application describes a specific method involving modified immunoresponsive cells that express a heterologous TCR, intended for therapeutic use.
This publication represents a new patent application filing and does not impose immediate compliance obligations on regulated entities. However, it signifies ongoing innovation in cancer therapeutics, particularly in cell-based treatments. Companies in the pharmaceutical and biotechnology sectors should monitor the progress of this and similar patent applications as they may impact future product development and intellectual property landscapes in oncology.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED T-CELLS FOR USE IN THE TREATMENT OF BLADDER CANCER
Application US20260083849A1 Kind: A1 Mar 26, 2026
Inventors
Stephen DAWE, Alejandro GARCIA-CONSUEGRA LÓPEZ-PICAZO, José María SARO SUAREZ
Abstract
The disclosure relates to a method of treating bladder cancer, and to a population of modified immunoresponsive cells expressing a heterologous TCR for use in such method.
CPC Classifications
A61K 40/4268 A61K 40/11 A61K 40/32 A61P 35/00 C07K 14/7051 C07K 16/30
Filing Date
2023-09-07
Application No.
19108853
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.